Cancer in the Transplant Recipient
Cancer in the Transplant Recipient
复制标题
DOI：
10.1101/cshperspect.a015677
复制
发表时间：
2013-07-01
影响因子：
5.4
通讯作者：
Wong, Germaine
中科院分区：
文献类型：
--
作者：
Chapman, Jeremy R.;Webster, Angela C.;Wong, Germaine
在过去的十年中，恶性肿瘤已成为移植后死亡的三大原因之一，因此在所有器官移植项目中变得越来越重要。通过筛查、预防、积极的危险因素管理和介入治疗的结合，心血管疾病和感染导致的死亡频率都在下降。另一方面，癌症的筛查效果较差且费用昂贵。除使用免疫抑制本身外，风险因素大多难以捉摸和/或难以产生影响；最后，对患有癌症的移植受者的治疗方法往往是虚无主义的。本文回顾了影响移植的每个问题：等待名单前的癌症、捐赠者的癌症传播、移植后的癌症、诊断出癌症后移植受者的结果，以及筛查和治疗在减少癌症对移植受者影响方面的作用。
Malignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ transplant programs. Death from cardiovascular disease and infection are both decreasing in frequency from a combination of screening, prophylaxis, aggressive risk factor management, and interventional therapies. Cancer, on the other hand, is poorly and expensively screened for; risk factors are mostly elusive and/or hard to impact on except for the use of immunosuppression itself; and finally therapeutic approaches to the transplant recipient with cancer are often nihilistic. This article provides a review of each of the issues as they come to affect transplantation: cancer before wait-listing, cancer transmission from the donor, cancer after transplantation, outcomes of transplant recipients after a diagnosis of cancer, and the role of screening and therapy in reducing the impact of cancer in transplant recipients.